1. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID‐19 vaccine—United States, December 2020;Oliver S;MMWR Morb Mortal Wkly Rep,2021
2. Vaccine‐associated hypersensitivity;McNeil MM;J Allergy Clin Immunol,2018
3. CDC.COVID‐19 vaccination: clinical considerations. Interim clinical considerations for use of mRNA COVID‐19 vaccines currently authorized in the United States.Atlanta GA:US Department of Health and Human Services CDC;2020.https://www.cdc.gov/vaccines/covid‐19/info‐by‐product/clinical‐considerations.html.
4. CDC.COVID‐19 vaccination: clinical considerations. Interim considerations: preparing for the potential management of anaphylaxis after COVID‐19 vaccination.Atlanta GA:US Department of Health and Human Services CDC;2020.https://www.cdc.gov/vaccines/covid‐19/clinical‐considerations/managing‐anaphylaxis.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid‐19%2Finfo‐by‐product%2Fpfizer%2Fanaphylaxis‐management.html.
5. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine—United States, December 14–23, 2020;CDC COVID‐19 Response Team;MMWR Morb Mortal Wkly Rep.,2021